Researcher
Herlinde Dumez
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From1 Oct 2005 → Today
Publications
21 - 30 of 64
- Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab(2018)
Authors: Tom van Cann, Patrick Schöffski, Paul Clement, Oliver Bechter, Isabel Spriet, Constantinus Politis, Joseph Schoenaers, Herlinde Dumez, Patrick Neven, Kristiaan Nackaerts, et al.
Pages: 100 - 109 - Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors(2018)
Authors: Tom van Cann, Annelies Verbiest, Paul Clement, Oliver Bechter, Ludo Willems, Isabel Spriet, Constantinus Politis, Joseph Schoenaers, Herlinde Dumez, Patrick Neven, et al.
Pages: 869 - 878 - Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial(2017)
Authors: Daniel P Petrylak, Ronald de Wit, Kim N Chi, Alexandra Drakaki, Cora N Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed Hussain, Aude Fléchon, Aristotelis Bamias, et al.
Pages: 2266 - 2277 - First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours(2017)
Authors: Patrick Schöffski, Herlinde Dumez
Pages: 240 - 247 - A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy(2017)
Authors: Herlinde Dumez
Pages: 2741 - 2746 - Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma(2017)
Authors: Paul Clement, Oliver Bechter, Herlinde Dumez, Annelies Verbiest, Raf Sciot, Daphne Hompes, Erik Van Limbergen, Patrick Schöffski
Pages: 1781087 - Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma(2016)
Authors: Oliver Bechter, Herlinde Dumez, Kevin Punie, Patrick Schöffski
Pages: 83 - 90 - A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies(2016)
Authors: Herlinde Dumez, Patrick Schöffski
Pages: 889 - 896 - Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor(2016)
Authors: Herlinde Dumez, Evelyne Lerut, Steven Joniau, Raymond Oyen, Patrick Schöffski, Benoit Beuselinck
Pages: 329 - 40 - A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors(2016)
Authors: Patrick Schöffski, Herlinde Dumez
Pages: 99 - 108